Whole blood expression was profiled in Relapsing Remitting Multiple Sclerosis patients
No associated publication
Specimen part, Disease
View SamplesWhole blood expression was profiled in Rheumatoid Arthiritis and SLE (Systemic LUPUS Erythomatosus) patients.
Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis.
Specimen part, Disease, Time
View SamplesThe whole blood was collected pre-treatment from rheumatoid arthritis patients starting the anti_TNF therapy. All patients were nave to anti_TNFs. The disease activity was measured using the DAS28 score at the pre-treatment visit1 (DAS28_v1) and 14 weeks after treatment visit3 (DAS28_v3). The response to the therapy was evaluated using the EULAR [European League Against Rheumatism] definition of the response. The objective of the data analysis was to identify gene expression coorelating with response as well as to identify genes that differentiate responders versus non-responders pre-treatment. The results of this investigation identified 8 trainscripts that predict responders vs. non-responders with 89% accuracy.
Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response.
Specimen part, Disease, Disease stage
View SamplesNOD mice were injected once a week with LTBR-Ig to block the LTBR-pathway, or with control monoclonal antibody MOPC from age 8 to 16 weeks old. Extraorbital lacrimal glands or submaxillary glands were dissected and total mRNA prepared. Each sample was either the combined lacrimals (2) from each mouse or individual salivary glands. There were 4 mice in each treatment group. Total mRNA was isolated and the quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Reverse transcription to prepare cDNA was performed using Invitrogen M-MLV system. The purpose was to determine changes in gene expression in glands due to blockade of the LTBR-pathway.
Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.
Specimen part, Treatment, Time
View SamplesTo test the efficacy of TNFR-Fc and anti-TWEAK mAb treatment alone and in combination
No associated publication
Specimen part
View SamplesTWEAK/Fn14 signaling may regulate the expression of genes involved in epithelial repair and mucosal inflammation. Comparing the gene signatures in WT and TWEAK KO mice will inform the biology of TWEAK/Fn14 pathway in the GI tract.
Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis.
Specimen part, Treatment
View SamplesTo test TWEAK/Fn14 pathway and relative agents in chronic TNBS colitis
TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice.
Specimen part
View Samples